Endothelial Monocyte-activating Polypeptide-II as an Endothelial Dysfunction Marker and Its Relation to the Oxidative Stress in Egyptian Sickle Patients

Age

2 to 18 Years

Phase

Phase 4

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

About the study

This study objectives to assess the role of endothelial monocyte-activating polypeptide II
(EMAP II) as a marker of endothelial dysfunction and disturbed angiogenesis in sickle cell
disease and to identify its correlation With the oxidative status.

participation requirements

– Patients with sickle cell disease as confirmed by qualitative and quantitative
analysis of hemoglobin using high performance liquid chromatography (HPLC) at their
steady state.

participation restrictions

– Patients with any inflammatory condition within one month prior to enrollment.